{"metadata": {"source": "psychonaut", "title": "Cannabidiol - PsychonautWiki", "description": "Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/CBD", "drug": "CBD", "cid": 644019, "char_count": 21724, "word_count": 3040, "doc_id": "doc_84", "num_chunks": 28, "chunk_id": "84::chunk_14", "document_index": 84, "latency_s": 0.829843700004858, "prompt_toks": 6301, "completion_toks": 75, "relevance_score": 0.02237146}, "content": "Drug: CBD | cid: 644019\nSource: psychonaut | Source description: Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.\n\n                    Text: \n                    Legal status\n\nInternationally, cannabidiol is not scheduled under the Convention on Psychotropic Substances or any other UN drug treaty.\n\nAustralia: Cannabidiol (in preparations for therapeutic use containing 2 per cent or less of other cannabinoids found in cannabis) was placed in Schedule 4 as a \"Prescription Only Medicine OR Prescription Animal Remedy\" in 2015. It was previously listed in Schedule 9 as a prohibited substance.[31]\n\nCanada: Cannabidiol is specifically listed in the Schedule II Controlled Drugs and Substances Act. However, in 2016 Canada’s \"Access to Cannabis for Medical Purposes Regulations\" came into effect. These regulations improve access to cannabis used for medicinal purposes, including CBD.[32]\n\nHong Kong: Illegal in Hong Kong since 1st February 2023, punishable by 7 years imprisonment.[33]\n\n\n                    Context: \n                    This section provides an overview of the international and national legal statuses of cannabidiol (CBD), detailing its scheduling and legal restrictions in various countries. It highlights regions where CBD is legal, regulated, or illegal, and specifies recent changes in jurisdictions like Australia, Canada, and Hong Kong. This information is crucial for understanding the legal considerations associated with CBD use and distribution worldwide.\n                "}
{"metadata": {"source": "psychonaut", "title": "Cannabidiol - PsychonautWiki", "description": "Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/CBD", "drug": "CBD", "cid": 644019, "char_count": 21724, "word_count": 3040, "doc_id": "doc_84", "num_chunks": 28, "chunk_id": "84::chunk_17", "document_index": 84, "latency_s": 0.5436048999981722, "prompt_toks": 6387, "completion_toks": 45, "relevance_score": 0.0067449897}, "content": "Drug: CBD | cid: 644019\nSource: psychonaut | Source description: Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.\n\n                    Text: \n                    References\n\n↑ Campos, A. C., Moreira, F. A., Gomes, F. V., Del Bel, E. A., Guimarães, F. S. (5 December 2012). \"Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders\". Philosophical Transactions of the Royal Society B: Biological Sciences. 367 (1607): 3364–3378. doi:10.1098/rstb.2011.0389. ISSN 0962-8436.\n\n↑ \"Epidiolex (Cannabidiol) FDA Label\" (PDF). fda.gov. Retrieved 28 June 2018. For label updates see FDA index page for NDA 210365\n\n↑ 3.0 3.1 FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy, 2018, retrieved 25 June 2018\n\n↑ LaVito, A., DEA reschedules Epidiolex, marijuana-derived drug, paving the way for it to hit the market\n\n↑ Angell, T. (2018), UN Launches First-Ever Full Review Of Marijuana’s Status Under International Law\n\n\n                    Context: \n                    This references section lists key scientific studies and official sources related to cannabidiol's mechanisms, medical approvals, and legal status, providing foundational evidence supporting the informational content of the full document on cannabidiol (CBD).\n                "}
{"metadata": {"source": "psychonaut", "title": "Cannabidiol - PsychonautWiki", "description": "Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.", "language": "en-GB", "url": "https://m.psychonautwiki.org/wiki/CBD", "drug": "CBD", "cid": 644019, "char_count": 21724, "word_count": 3040, "doc_id": "doc_84", "num_chunks": 28, "chunk_id": "84::chunk_15", "document_index": 84, "latency_s": 0.8761873999901582, "prompt_toks": 6320, "completion_toks": 72, "relevance_score": 0.0043483814}, "content": "Drug: CBD | cid: 644019\nSource: psychonaut | Source description: Cannabidiol (also known as CBD and Epidiolex®) is a naturally-occurring cannabinoid found in the cannabis plant. It is one of some 113 identified cannabinoids in cannabis plants, accounting for up to 40% of the plant's extract.[1] It does not possess the same psychoactivity as tetrahydrocannabinol (THC), which is responsible for the euphoric and hallucinogenic aspects of cannabis, and is typically described as non-intoxicating.\n\n                    Text: \n                    Hong Kong: Illegal in Hong Kong since 1st February 2023, punishable by 7 years imprisonment.[33]\n\nNew Zealand: Cannabidiol is a controlled substance in New Zealand. However, by passing the Misuse of Drugs Amendment Regulations 2017 in September 2017, many of the restrictions currently imposed by the regulations are removed since then. The changes will mean that CBD products, where the level of other naturally occurring cannabinoids is less than 2% of the cannabinoid content, will be easier to access for medical use.[34]\n\nSwitzerland: Cannabidiol is not subject to the Narcotics Act in Switzerland because it does not produce a psychoactive effect. It is still subject to standard Swiss legislation.[35]\n\nUnited Kingdom: In 2016, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a statement that products containing CBD used for medical purposes are considered as a medicine subject to standard licensing requirements.[36]\n\n\n                    Context: \n                    This excerpt summarizes the legal status of cannabidiol (CBD) in various countries, highlighting recent regulations and enforcement. It details restrictions and allowances in Hong Kong, New Zealand, Switzerland, and the United Kingdom, providing key regulatory updates relevant to understanding CBD's legal landscape globally. This information is essential for users seeking legal guidance on CBD use across different jurisdictions.\n                "}
